Sanofi joins forces with U.S. Department of Health and Human Services to advance a novel coronavirus vaccine
18 Fevereiro 2020 - 12:00PM
Sanofi joins forces with U.S. Department of Health and Human
Services to advance a novel coronavirus vaccine
Sanofi joins forces with U.S. Department of Health and
Human Services to advance a novel coronavirus vaccine
*Work with Biomedical Advanced Research and Development
Authority (BARDA) will utilize Sanofi’s well-established
recombinant technology platform to expedite a potential COVID-19
vaccine
PARIS – February 18, 2020 –
Sanofi Pasteur, the vaccines global business unit of Sanofi, will
leverage previous development work for a SARS vaccine which may
unlock a fast path forward for developing a COVID-19 vaccine.
Sanofi will collaborate with the Biomedical Advanced Research and
Development Authority (BARDA), part of the Office of the Assistant
Secretary for Preparedness and Response, expanding the company’s
long-standing partnership with BARDA.
COVID-19 belongs to a family of coronaviruses
that can cause respiratory disease. In late 2002, the SARS (severe
acute respiratory syndrome) coronavirus emerged and then largely
disappeared by 2004. Sanofi plans to further investigate an
advanced pre-clinical SARS vaccine candidate that could protect
against COVID-19.
“Addressing a global health threat such as this
newest coronavirus is going to take a collaborative effort, which
is why we are working with BARDA to quickly advance a potential
vaccine candidate,” said David Loew, Global Head of Vaccines at
Sanofi. “While we are lending our expertise where possible, we
believe the collaboration with BARDA may provide the most
meaningful results in protecting the public from this latest
outbreak.”
Sanofi to utilize innovative recombinant
technology platform
Sanofi will use its recombinant DNA platform to
produce a 2019 novel coronavirus vaccine candidate. The
recombinant technology produces an exact genetic match to proteins
found on the surface of the virus. The DNA sequence encoding this
antigen will be combined into the DNA of the baculovirus expression
platform, the basis of Sanofi’s licensed recombinant influenza
product, and used to rapidly produce large quantities of the
coronavirus antigen which will be formulated to stimulate the
immune system to protect against the virus.
“Emerging global
health threats like the 2019 novel coronavirus require a rapid
response,” said BARDA Director Rick A. Bright, Ph.D. “By
expanding our partnership
with Sanofi Pasteur and leveraging a licensed
recombinant vaccine platform, we hope to speed development of a
vaccine candidate to protect against a new virus.”
Sanofi uniquely positioned in search for
a coronavirus vaccine
In non-clinical studies, the SARS vaccine
candidate was immunogenic and afforded partial protection as
assessed in animal challenge models. This development work by
Protein Sciences (acquired by Sanofi in 2017) provides a head start
in expediting a COVID-19 vaccine. Additionally, since there is a
licensed vaccine based on this platform this will allow for
research and materials to be produced relatively quickly for
clinical testing. Sanofi’s platform also has the potential to
manufacture large quantities of the vaccine candidate.
Sanofi’s long-standing commitment to
protecting public health
This agreement with BARDA marks another
milestone in Sanofi’s ongoing contributions to help fight public
health threats. Sanofi continues to actively explore
potential opportunities where the company’s deep vaccine experience
and innovative technologies may contribute to addressing the
coronavirus public health situation, including sharing Sanofi’s
vaccine research and development experience with the Coalition for
Epidemic Preparedness Innovations.
In December 2019, Sanofi also entered into an
agreement with BARDA to establish state of the art facilities in
the U.S. for the sustainable production of an adjuvanted
recombinant vaccine for use in the event of an influenza pandemic
and based on the same technology platform that will be used for the
COVID-19 program.
About Sanofi Sanofi is dedicated to
supporting people through their health challenges. We are a global
biopharmaceutical company focused on human health. We prevent
illness with vaccines, provide innovative treatments to fight pain
and ease suffering. We stand by the few who suffer from rare
diseases and the millions with long-term chronic
conditions. With more than 100,000 people in 100 countries,
Sanofi is transforming scientific innovation into healthcare
solutions around the globe. Sanofi, Empowering Life |
Media Relations
Contact Marion Breyer Tel.: +33 (0)1 53 77 46 46
mr@sanofi.com |
Investor
Relations Contact Felix Lauscher Tel.: +33 (0)1 53 77 45
45 ir@sanofi.com |
Forward-Looking
Statements This press release contains
forward-looking statements as defined in the Private Securities
Litigation Reform Act of 1995, as amended. Forward-looking
statements are statements that are not historical facts. These
statements include projections and estimates and their underlying
assumptions, statements regarding plans, objectives, intentions and
expectations with respect to future financial results, events,
operations, services, product development and potential, and
statements regarding future performance. Forward-looking statements
are generally identified by the words “expects”, “anticipates”,
“believes”, “intends”, “estimates”, “plans” and similar
expressions. Although Sanofi’s management believes that the
expectations reflected in such forward-looking statements are
reasonable, investors are cautioned that forward-looking
information and statements are subject to various risks and
uncertainties, many of which are difficult to predict and generally
beyond the control of Sanofi, that could cause actual results and
developments to differ materially from those expressed in, or
implied or projected by, the forward-looking information and
statements. These risks and uncertainties include among other
things, the uncertainties inherent in research and development,
future clinical data and analysis, including post marketing,
decisions by regulatory authorities, such as the FDA or the EMA,
regarding whether and when to approve any drug, device or
biological application that may be filed for any such product
candidates as well as their decisions regarding labelling and other
matters that could affect the availability or commercial potential
of such product candidates, the absence of guarantee that the
product candidates if approved will be commercially successful, the
future approval and commercial success of therapeutic alternatives,
Sanofi’s ability to benefit from external growth opportunities, to
complete related transactions and/or obtain regulatory clearances,
risks associated with intellectual property and any related pending
or future litigation and the ultimate outcome of such
litigation, trends in exchange rates and prevailing interest
rates, volatile economic conditions, the impact of cost containment
initiatives and subsequent changes thereto, the average number of
shares outstanding as well as those discussed or identified in the
public filings with the SEC and the AMF made by Sanofi, including
those listed under “Risk Factors” and “Cautionary Statement
Regarding Forward-Looking Statements” in Sanofi’s annual report on
Form 20-F for the year ended December 31, 2018. Other than as
required by applicable law, Sanofi does not undertake any
obligation to update or revise any forward-looking information or
statements. |
Sanofi (EU:SAN)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Sanofi (EU:SAN)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024